Most thyroid nodules are benign. Only 5% to 15% turn out to be cancerous, which means the odds are strongly in your favor. But telling the difference between a harmless nodule and a malignant one requires a combination of ultrasound imaging, biopsy results, and sometimes molecular testing. No single test gives a definitive answer on its own.
What Ultrasound Reveals
Ultrasound is the first and most important tool for evaluating a thyroid nodule. Radiologists look for a specific set of features that raise or lower suspicion. The most consistent signs of malignancy are spiculated (jagged or spiky) margins, microcalcifications, a shape that is taller than it is wide, and markedly dark echogenicity compared to surrounding tissue.
Each of these features carries different weight. Spiculated margins have a specificity of about 92%, meaning that when this feature appears, it rarely turns out to be benign. Marked hypoechogenicity (the nodule appearing very dark on ultrasound) is similarly specific, at 92% to 94%. Microcalcifications, which are tiny bright spots corresponding to calcium deposits commonly found in papillary thyroid cancer, have a specificity of 86% to 95%.
On the other hand, nodules that appear mostly fluid-filled (cystic), have smooth borders, and look similar in brightness to the surrounding thyroid tissue are much more likely to be benign. A purely cystic nodule is almost never cancerous.
Radiologists use scoring systems like TI-RADS to combine these individual features into an overall risk category. That risk category, along with the nodule’s size, determines whether a biopsy is recommended. Current American Thyroid Association guidelines suggest biopsy for intermediate and high-risk nodules at 10 mm or larger, and for low-risk nodules at 15 mm or larger.
Physical Symptoms That Raise Concern
Most thyroid nodules cause no symptoms at all, and most thyroid cancers don’t either in their early stages. That’s why imaging matters so much. But as a cancerous nodule grows, it can produce warning signs that benign nodules typically don’t.
The red flags include a new or growing lump you can feel through the skin on your neck, hoarseness or other voice changes that don’t resolve, difficulty swallowing, pain in the neck or throat, and swollen lymph nodes in the neck. A nodule that feels hard and fixed in place (not movable) is more suspicious than one that shifts freely under your fingers. Rapid growth is particularly concerning, as the most aggressive form, anaplastic thyroid cancer, can cause neck swelling that worsens quickly enough to interfere with breathing.
How Biopsy Works
Fine-needle aspiration (FNA) is the standard method for sampling a thyroid nodule. A thin needle is inserted into the nodule, usually guided by ultrasound, and cells are withdrawn for examination under a microscope. It’s typically done in an office setting and takes about 20 minutes.
For most nodules, FNA is highly reliable. The false-negative rate for nodules smaller than 4 cm is about 1.3%. For larger nodules (over 4 cm), that rate climbs to roughly 4% to 10%, because a single needle sample may not capture the most concerning area in a large mass. This is why doctors sometimes take multiple samples from different parts of a large nodule.
Biopsy results are reported using the Bethesda system, a six-tier scale ranging from Category I (not enough cells to make a diagnosis) to Category VI (definitively malignant). Categories II through VI represent a sliding scale of suspicion. A Category II result is benign. Categories III and IV are considered “indeterminate,” meaning the cells look unusual but can’t be classified as clearly benign or malignant. Category V is suspicious for malignancy, and Category VI is confirmed cancer.
When Biopsy Results Are Unclear
About 15% to 30% of FNA biopsies come back as indeterminate. This is where molecular testing becomes valuable. Rather than sending every patient with an unclear biopsy straight to surgery, doctors can order genetic analysis of the same biopsy sample to look for mutations associated with thyroid cancer.
Two widely used tests are Afirma GSC and ThyroSeq v3. Afirma GSC analyzes gene expression patterns and was designed to identify nodules that are almost certainly benign, sparing those patients from surgery. ThyroSeq v3 screens 112 genes for point mutations, fusions, and other alterations linked to thyroid cancer. A third option, the multiplatform approach from Interpace Diagnostics, combines a mutation panel with a microRNA classifier to provide both high positive and negative predictive values.
These tests are most useful for nodules in Bethesda Categories III and IV. A “benign” molecular result gives you and your doctor confidence to monitor the nodule rather than operate. A “suspicious” result tips the balance toward surgery. One important caveat: certain genetic changes, particularly RAS mutations, are found in both low-grade, non-invasive tumors and true cancers, so a suspicious molecular result doesn’t always mean aggressive disease.
What Blood Tests Can Tell You
Standard blood work doesn’t diagnose thyroid cancer, but it provides useful context. TSH, the hormone that stimulates the thyroid, has a documented relationship with malignancy risk. In one study of patients with normal thyroid function, those with malignant nodules had significantly higher average TSH levels (1.94) compared to those with benign nodules (1.62). A TSH level above 2 mIU/L was significantly more common in cancerous nodules. The higher the TSH, the higher the Bethesda category tended to be.
This doesn’t mean elevated TSH causes cancer. But when combined with suspicious ultrasound features, a higher TSH level adds one more data point that nudges toward biopsy. Conversely, a very low TSH may suggest the nodule is a “hot” or overactive nodule, which is almost always benign. In that case, a radioactive iodine uptake scan is often the next step instead of biopsy.
Risk Factors That Increase Suspicion
Certain personal characteristics make a nodule more likely to be cancerous, even before any testing. The most well-established risk factor is a history of radiation exposure to the head or neck, particularly during childhood. Children exposed before age 4 have a fivefold greater risk per unit of radiation dose compared to those exposed at ages 10 to 14. The risk is significantly elevated at radiation doses to the thyroid as low as 50 to 100 milligray, and it rises with increasing dose.
Other factors that raise suspicion include a family history of thyroid cancer (especially in a first-degree relative), being male (nodules are more common in women, but when men have them, the malignancy rate is higher), and age extremes. Nodules in people under 20 or over 60 carry a higher probability of cancer than those found in middle-aged adults. A personal or family history of other head and neck tumors in someone who was exposed to radiation further increases concern.
Monitoring Low-Risk Nodules
If your nodule has reassuring ultrasound features, a benign biopsy result, and no concerning risk factors, active surveillance is the typical approach. This means periodic ultrasound exams to check whether the nodule changes in size or appearance over time. The first follow-up is usually 6 to 12 months after the initial evaluation, with intervals extending to every 1 to 2 years if the nodule remains stable.
Growth alone doesn’t confirm cancer. Benign nodules can grow slowly over time. What matters is a pattern of growth combined with changing ultrasound characteristics, such as new microcalcifications, increasingly irregular margins, or a shift from partially cystic to solid. A repeat biopsy is warranted if any of these changes develop. Most people monitored this way never need surgery, and the handful whose nodules do eventually show concerning changes are caught early enough for straightforward treatment.